Samsung Bioepis predicts biosimilars will save US$181B in five years in the US

Apr 18, 2023

Samsung Bioepis released its first US Biosimilar Market Report which found that biosimilars will save the US healthcare system $181B in the next five years.  The report will be published each quarter after the Center of Medicare, Medicaid Services publishes new data.  Key findings from the report include:

  • On average, biosimilars gained 53% market share in the three years after their initial launch. This was influenced by the faster acceptance (75%) for oncology compared to other therapeutic areas (25%) and for pegfilgrastim compared to other molecules
  • Average sales prices declined 41% on average three years after first biosimilar launch. The prices for oncology biosimilars experienced the steepest decline (each dropping >50% in the first three years after biosimilar launch)
  • Unbranded insulin glargines are discounted by up to 66% compared to Lantus® (Sanofi)
  • As of Q4 2022 the biosimilar share of the trastuzumab market has reached 82%
Print Page Mail Article